Showing 361 - 380 results of 651 for search '"oncology"', query time: 0.06s Refine Results
  1. 361
  2. 362

    New biomarkers for diagnosis of bladder cancer: a bibliometric analysis by Roberto Falabella, Valentina De Simone, Felice Crocetto, Francesco Del Giudice, Angelo Porreca, Nazario Foschi, Biagio Barone, Luca Di Gianfrancesco, Valentina Di Pasquale, Vincenzo Francesco Caputo

    Published 2025-02-01
    “…The journals that produced the most publications and received the highest number of citations were Cancers, International Journal of Molecular Sciences, and Frontiers in Oncology, confirming their role in producing high-impact research. …”
    Get full text
    Article
  3. 363
  4. 364
  5. 365
  6. 366
  7. 367
  8. 368
  9. 369

    Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

    Published 2025-03-01
    “…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received pemetrexed (500 mg/m2) and pembrolizumab (200 mg) on day 1 of each 21-day cycle. …”
    Get full text
    Article
  10. 370
  11. 371
  12. 372
  13. 373
  14. 374
  15. 375
  16. 376
  17. 377
  18. 378

    Diagnostic efficacy of serological and epigenetic methods of screening diagnostics of colorectal cancer by O. I. Kit, D. V. Burtsev, A. Yu. Maksimov

    Published 2014-12-01
    “…Control group included 213 CRC patients who have addressed oncologic institutions for intestinal or general complaints independently. …”
    Get full text
    Article
  19. 379
  20. 380